Literature DB >> 32775808

Treatment Outcome of Acquired Retinal Pigment Epithelial Tumors with Rhuthenium-106 Plaque Radiotherapy: Experience on Two Cases.

Masood Naseripour1, Ahad Sedaghat1, Parya Abdolalizadeh1, Ehsan Azizi1.   

Abstract

PURPOSE: To report the clinical outcome of rhuthenium-106 plaque radiotherapy in acquired retinal pigment epithelial (RPE) tumors.
METHODS: In this interventional case series, two eyes of two patients with clinically diagnosed ocular-acquired RPE tumors including adenoma and adenocarcinoma underwent plaque radiotherapy with rhuthenium-106. The clinical findings and visual outcome of the patients were evaluated.
RESULTS: The first patient was a 44-year-old male, and the second was a 32-year-old female. The follow-up times were 24 and 32 months. The tumor was unilateral and hyperpigmented in both cases, located at juxtapapillary in one patient and on peripheral part of the retina in the other. Vitreous hemorrhage and peripheral exudation were obvious in one patient. Macular edema, epiretinal membrane, and retinal feeder vessels were also detected in the examination. The patients underwent plaque radiotherapy with rhuthenium-106 as the first step of management. The tumor has been stable until the last follow-up in both patients with globe preservation and acceptable visual acuity (5/10 for the first case and 4/10 for the second case).
CONCLUSION: Rhuthenium-106 plaque radiotherapy might be a conservative therapy in the management of acquired RPE tumors and prevent early enucleation. Copyright:
© 2020 Journal of Current Ophthalmology.

Entities:  

Keywords:  Ocular oncology; Retinal pigment epithelium; Retinal pigment epithelium adenoma; Rhuthenium-106 plaque radiotherapy

Year:  2020        PMID: 32775808      PMCID: PMC7382525          DOI: 10.4103/JOCO.JOCO_144_20

Source DB:  PubMed          Journal:  J Curr Ophthalmol        ISSN: 2452-2325


INTRODUCTION

Acquired tumors of the retinal pigment epithelium (RPE), including adenoma and adenocarcinoma, are an exceedingly rare intraocular tumor, usually diagnosed in adulthood, with an age range of 26–80 years at the time of diagnosis and no obvious gender dominancy.123 Clinical differentiation between adenoma and adenocarcinoma is generally difficult and made based on the pathology.2 There is no accepted algorithm for the management of acquired RPE tumors. They are usually confined to the orbit and do not metastasize despite histopathological features of invasion. They are also clinically misdiagnosed with choroidal melanoma. Therefore, some ocular oncologists prefer enucleation to achieve definite diagnosis and treatment.45678 However, limited trials of other modalities such as local tumor resection,91011 laser photocoagulation,12 cryotherapy,31213 radiation,311 and a combination of them have also been reported to preserve the globe and a trend away from enucleation as much as possible. In this study, we report our experience of two patients with acquired RPE tumors who were managed by rhuthenium-106 plaque radiotherapy as a globe preservation approach.

CASE REPORT

Medical records of patients with acquired RPE tumors who were referred to the ophthalmology clinic at a university-based hospital (Rassoul Akram Hospital, Tehran, Iran) or senior author's (M.N.) private clinic were reviewed from August 2016 to October 2019. This study adhered to the tenets of the Declaration of Helsinki and informed consent was obtained from two patients. The diagnosis of RPE tumors was done based on the clinical features, funduscopy examination, and results of ancillary tests including A-scan, B-scan, fluorescein angiography, and optical coherence tomography (OCT). Two patients underwent plaque radiotherapy with rhuthenium-106 as the first step of management. Patients underwent comprehensive ophthalmologic examination, including best corrected visual acuity (BCVA), funduscopy, and intraocular pressure measurement in follow-up visits as well as ancillary tests to confirm the stability or regression of the lesion. Table 1 shows the overview of two cases explained below.
Table 1

Demographic and clinical features of two patients with acquired retinal pigment epithelial tumors

Patient numberAgeSexYears of diagnosisInitial BCVALast BCVADuration of follow-upLocation of tumorInitial thicknessFinal thicknessAssociated findingsManagement
144Male20165/105/1024 monthsJuxtapapillary4.53.5Vitreous hemorrhage, macular edemaPlaque therapy, IVB
232Female20174/104/1032 monthsSupratemporal quadrant in the periphery5.53Peripheral exudation, feeder vessels, ERMPlaque therapy, IVB

BCVA: Best corrected visual acuity, IVB: Intravitreal bevacizumab, ERM: Epiretinal membrane

Demographic and clinical features of two patients with acquired retinal pigment epithelial tumors BCVA: Best corrected visual acuity, IVB: Intravitreal bevacizumab, ERM: Epiretinal membrane

Case 1

A 44-year-old male was referred to our clinic in August 2016 for a progressive loss of vision in his left eye from 4 months earlier. His visual acuity was 10/10 OD and 5/10 OS. Intraocular pressure was normal in both eyes. Examination of the right eye was not contributory. Funduscopy showed resolving vitreous hemorrhage and related media haziness that prevented well evaluation of the fovea and hyperpigmented mass in supranasal quadrant, 5 mm away from the disc. There was no obvious feeder vessel. The tumor dimensions were 7 mm × 6 mm in size and 4.95 mm in maximum height [Figure 1a]. Fluorescein angiography revealed early hypofluorescence, late mottle hyperfluorescence areas in the lesion, and petaloid pattern in fovea [Figure 2]. OCT confirmed cystoid macular edema. The ultrasonography showed dome-shaped solid mass with medium-to-high internal reflectivity and no choroidal excavation. The patient underwent plaque radiotherapy with rhuthenium-106 after 5 months because the patient refused treatment for a while. The BCVA was 3/10 in 3 months after plaque radiotherapy. The thickness of the tumor was 4.91 mm. Due to persistent vitreous hemorrhage and cystoid macular edema, intravitreal bevacizumab was injected two times. After 24 months follow-up, the vision was 5/10, and tumor thickness decreased to 3.37 mm [Figure 1b].
Figure 1

On B-scan ultrasound image of the left eye of the Case 1: paraxial section shows nodular, highly reflective fundus mass that had a thickness of 4.95 mm before plaque radiotherapy (a) decreasing to 3.37 mm, 24 months after plaque therapy (b)

Figure 2

Fluorescein angiography of the left eye of Case 1 at early (a), mid (b), and late (c) phases, demonstrating early hypo and late patchy hypofluorescent and hyperfluorescent retinal pigment epithelium alterations

On B-scan ultrasound image of the left eye of the Case 1: paraxial section shows nodular, highly reflective fundus mass that had a thickness of 4.95 mm before plaque radiotherapy (a) decreasing to 3.37 mm, 24 months after plaque therapy (b) Fluorescein angiography of the left eye of Case 1 at early (a), mid (b), and late (c) phases, demonstrating early hypo and late patchy hypofluorescent and hyperfluorescent retinal pigment epithelium alterations

Case 2

A 32-year-old woman presented with a complaint of progressive visual loss of the left eye from 8 months earlier. The examination of the right eye was within the normal limit. The BCVA of the left eye was 4/10. In the left posterior segment examination, there was a hyperpigmented mass with obvious large feeder vessels surrounded by extensive exudates in the supratemporal quadrant [Figure 3a]. Epiretinal membrane was another finding. The tumor size was 7 mm × 7 mm, and maximum thickness was measured 5.5 mm. Ultrasonography revealed solid dome-shaped mass with medium-to-high internal reflectivity. The fluorescein angiography showed large tortuous retinal feeder vessels without leakage [Figure 3b]. Plaque radiotherapy with ruthenium-106 was done. After 7 months, the exudation was completely absorbed, and the tumor regressed. The final BCVA remained 1/10 [Figure 4a-c]. Later, the patient developed radiation retinopathy and central macular edema, whereas the thickness of the tumor reduced to 3 mm after 32 months of plaque radiotherapy.
Figure 3

Color fundus photography (a) and fluorescein angiography (b) of the left eye of Case 2 which shows a pigmented mass with feeder vessels in supratemporal quadrant

Figure 4

Color fundus photography of Case 2 after 1 month (a), 3 months (b), and 7 months (c) plaque radiotherapy

Color fundus photography (a) and fluorescein angiography (b) of the left eye of Case 2 which shows a pigmented mass with feeder vessels in supratemporal quadrant Color fundus photography of Case 2 after 1 month (a), 3 months (b), and 7 months (c) plaque radiotherapy

DISCUSSION

Most cases of acquired RPE tumors represent a diagnostic dilemma for the clinician since they may masquerade as choroidal malignant melanoma.46101314 Since tumors of the RPE have no potential for metastasis, and the treatment of these entities may differ, it would be desirable to identify the specific features of each lesion [Table 2]. On the other hand, RPE tumors can rarely mimic a choroidal hemangioma with slowly progression.8 It is also difficult to differentiate acquired RPE tumors from other proliferative conditions of the RPE such as congenital hypertrophy RPE (CHRPE) and reactive hyperplasia. Although acquired RPE tumors, including adenoma and adenocarcinoma usually develop in otherwise normal eyes,234915161718 it occasionally arises from a staphyloma,5 juxtapapillary histoplasmosis scar,6 CHRPE,101119 phthisic eye,520 chorioretinal scar following a subfoveal neovascular membrane14 or previous ocular inflammation.3
Table 2

Comparing different characteristics of choroidal melanoma and acquired retinal pigment epithelial tumors

MelanomaAcquired RPE tumors
Dark black colorSometimesUsual
Surrounding pigmented choroidal baseUsualRare
Dilated vessel typeVeinsArtery and vein
Extensive exudateRareUsual
Exudative retinal detachmentSerousYellow exudate
Pattern of fluorescein angiographyEarlier hyperfluorescence and late intense stainingEarly hypofluorescence and late spot-like staining
Choroidal blood supply (double circulation in fluorescein angiography)UsualRare
Internal reflectivity in A-scanLowHigh
Mushroom shape in B-scanUsualRare
Peripheral margin in B-scanSlopingAbruptly elevated
Acoustic hollowness in B-scanUsualRare
Systemic metastasisUsualRare

RPE: Retinal pigment epithelium

Comparing different characteristics of choroidal melanoma and acquired retinal pigment epithelial tumors RPE: Retinal pigment epithelium Acquired RPE tumors are heterogeneous in their clinicopathological appearance. RPE tumors are solitary and unilateral with different sizes. Visual acuity may range between 20/20 to no light perception. Tumors have been located most often in the peripheral fundus49101621 and sometimes at the posterior pole.51419 They may occur close to optic disc.61517 Although acquired RPE tumors are generally darkly pigmented,491516 they can also present as an amelanotic pink-red and fleshy masses.617 Tumors arising from CHRPE can be amelanotic with pigmentation in the deeper part.11 It seems that as these tumors proliferate, some of them lose pigmentation.11 Since RPE tumors occur internal to the Bruch membrane, it is uncommon to observe a classic mushroom or collar-button configuration.14 The characteristic of acquired RPE tumor is an abruptly elevated mass and sharp borders without hyperpigmentation of surrounding choroidal base.36 Vitreous seeding has been reported in some cases.715 Tumors of RPE are more likely to produce vitreous seeding and hemorrhages if the tumor breaks through the sensory retina.310 One of our patients also developed vitreous hemorrhage without obvious vitreous seeding. Another distinguishing feature of the acquired RPE tumors is the development of a retinal feeder vessel. Therefore, it is not uncommon for these tumors to exhibit a dilated feeding retinal artery and a drainage retinal vein on fluorescein angiography.371822 Shields et al. found that 8 of 13 (61.5%), RPE tumors had dilated retinal vessels.3 RPE tumors can also produce extensive yellow exudation often leading to exudative retinal detachment.1316 Preretinal gliosis and cystoid macular edema61112 are frequently associated with RPE neoplasia. Retinal and subretinal fibrosis,14 surface wrinkling retinopathy,11 macular hole, significant ocular inflammation such as uveitis91516 or nonspecific choroiditis,35 secondary cataract,781118 and secondary glaucoma5818 may be found in patients with acquired RPE tumors.3 Ancillary tests may provide some helpful hints in the diagnosis of tumors of the RPE. Transillumination may71118 or may not619 show blockage of light by the tumor. Ocular ultrasonography demonstrates tumors of the RPE to have abruptly elevated dome-shaped mass3617 and acoustic solidity13617 in B-scan as well as high-to-medium internal reflectivity in A-scan.136817 Some cases have been reported as collar button shape,18 nodular,19 or mushroom shape,19 with low to medium internal reflectivity15 and with choroidal excavation15 in ultrasonography. Although rare, invasion of the tumor into the adjacent uveal stroma, sensory retina, and vitreous may be seen.3 Angiographic pattern may have a correlation with the structural characteristics of the tumor. Fluorescein angiography reveals some of the gross anatomical features of the tumor, and it is helpful in detecting and defining some of the structural alterations in the tumor tissue.16 Fluorescein angiography typically shows early hypofluorescence of the tumor during the filling phases, with continued relative hypofluorescence with multiple hyperfluorescent zones and spots,91519 and sometimes, leakage into the vitreous311 in the late frames. Early and late hyperfluorescence areas are due to the window defects and late staining related to sparsely pigmented cells in a more abundant stroma.16 However, there are some reports that describe the tumor as early and late hyperfluorescent in fluorescein angiography.61116 Fluorescein angiography may sometimes demonstrate the retinal blood supply1416 and lack of prominent choroidal vessels (double circulation) or extensive internal vascularity that typify some melanomas.3 Only the second case of our series had obvious feeder vessels in fluorescein angiography, and the other did not show specific pictures. Indocyanine green angiography reveals intratumoral hyperfluorescence and the presence of intratumoral feeder vessels without associated choroidal vessel dilation that seems to anastomose with retinal vessels.81419 Enhanced-depth imaging-OCT shows the tumor surface as irregular or “rugged” with full-thickness retinal tumor and dense posterior optical shadowing.23 No consensus exists in the management modalities of acquired RPE tumors. There are many reasons for this following dilemma: (1) RPE tumors are very rare and (2) RPE tumors are generally considered to be benign lesions with no tendency to metastasize despite their aggressive nature. Therefore, they can grow and cause profound visual loss.3818 When the tumor is small and asymptomatic, periodic observation with fundus photography is reasonable unless progressive or symptomatic lesions such as lipid exudates begin to develop.356 While enucleation has been the most commonly used treatment because of poor vision, significant local inflammation, pain, or suspicion of melanoma,456 other treatment modalities have also been tried to avoid globe loss as much as possible. For lesions located in the posterior fundus, the precise role of laser photocoagulation and cryotherapy is not determined, but such modalities could be attempted in patients with early growth or visually threatening complications.31213 The efficacy of local resection is also uncertain despite relative success in some peripherally located cases.910 The results of radiation therapy in the acquired RPE tumors have not been conclusive till now. Nakamura et al.8 reported the failure of external-beam radiation to control the symptoms of a patient with RPE adenoma who eventually required enucleation. Shields and Shields mentioned plaque radiotherapy can be used for medium-sized or larger tumors of RPE adenoma in eyes with good vision.24 They observed decreased tumor size without improvement in the visual acuity after iodine-25 plaque brachytherapy in two tumors of RPE with progressive enlargement, visual loss, and increasing exudation.24 On the other hand, Finger et al.21 did not achieve acceptable outcomes after palladium-103 plaque radiotherapy in a subject of RPE adenocarcinoma who underwent enucleation within 6 months. However, plaque radiotherapy with rhuthenium-106 completely stabilized the progressive complications of acquired RPE tumors (adenoma versus adenocarcinoma) in two patients of this series despite relatively poor outcomes in the visual acuity (first case) that was consistent with Shields and Shields report.24 The systemic prognosis of RPE tumors is excellent. None of the RPE tumors reported so far has been associated with metastasis, except in one atypical case with underlying trisomy 21, showing aggressive intraorbital and intracranial optic nerve invasion and multiple intracerebral metastases.25 Loeffler et al. also reported a case of RPE malignancy with suspected extraocular extension.20 Some authors believe that an adenocarcinoma of the RPE with extrascleral extension is capable of metastasis to distant sites.21 In contrast to systemic involvement, RPE tumors have variable growth potential and the capacity for locally invasive behavior. Although acquired RPE tumors are usually stable for a long time in their clinical course,6718 they tend to exhibit progression and local involvement of the choroid,1101517 sensory retina,71822 and rarely, extrascleral extension,20 leading to ocular complications and visual loss with time. In conclusion, plaque radiotherapy can be tried in cases suspicious to acquired RPE tumors that are diagnosed clinically without definite histopathological specimens, especially with good visual acuity, before thinking about more invasive approaches such as enucleation.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  23 in total

1.  Retinal Pigment Epithelial Adenocarcinoma Presenting as an Amelanotic Mass.

Authors:  Kendra A Klein; David R Lally; Lauren S Taney; Nora V Laver; Jay S Duker
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

2.  Malignant tumor of the retinal pigment epithelium with extraocular extension in a phthisical eye.

Authors:  K U Loeffler; T Kivelä; H Borgmann; H Witschel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

3.  Pathological condition of the retinal pigment epithelium. Neoplasms and nodular non-neoplastic lesions.

Authors:  M O Tso; D M Albert
Journal:  Arch Ophthalmol       Date:  1972-07

4.  Juxtapapillary retinal pigment epithelial tumor. Adenocarcinoma vs reactive hyperplasia.

Authors:  G C Graham
Journal:  Arch Ophthalmol       Date:  1971-03

5.  Adenocarcinoma arising from congenital hypertrophy of retinal pigment epithelium.

Authors:  J A Shields; C L Shields; R C Eagle; A D Singh
Journal:  Arch Ophthalmol       Date:  2001-04

6.  Neoplasms of the retinal pigment epithelium: the 1998 Albert Ruedemann, Sr, memorial lecture, Part 2.

Authors:  J A Shields; C L Shields; K Gündüz; R C Eagle
Journal:  Arch Ophthalmol       Date:  1999-05

7.  Adenocarcinoma of retinal pigment epithelium arising from a juxtapapillary histoplasmosis scar.

Authors:  J A Shields; R C Eagle; C C Barr; C L Shields; D E Jones
Journal:  Arch Ophthalmol       Date:  1994-05

8.  Adenocarcinoma of retinal pigment epithelium.

Authors:  S Ramahefasolo; G Soubrane; P Dhermy; V Godel; L Regenbogen; G Coscas
Journal:  Br J Ophthalmol       Date:  1987-07       Impact factor: 4.638

9.  Aggressive metastasising adenocarcinoma of the retinal pigment epithelium with trisomy 21.

Authors:  L M Heindl; G O H Naumann; F E Kruse; L M Holbach
Journal:  Br J Ophthalmol       Date:  2008-03       Impact factor: 4.638

10.  Malignant transformation of congenital hypertrophy of the retinal pigment epithelium.

Authors:  Jerry A Shields; Ralph C Eagle; Carol L Shields; Gary C Brown; Sara E Lally
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.